Compare GSK plc (GSK) vs Vanguard International High Dividend Yield ETF (VYMI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Vanguard International High Dividend Yield ETF — how do they compare? GSK plc trades at $46.6 (market cap $91.88B), while Vanguard International High Dividend Yield ETF trades at $100.49 (market cap $22.80B). The key difference: GSK plc is far larger — about 4× Vanguard International High Dividend Yield ETF's market cap, and GSK plc pays a 3.9% dividend while Vanguard International High Dividend Yield ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Vanguard International High Dividend Yield ETF for 50 Days on average.
| GSK | VYMI | |
|---|---|---|
Market Cap | $91.88B | $22.80B |
Volume | 7,730,529 | 748,441 |
Sector | Health | Broad Market / Factor |
52-Week High | $61.18 | $107.13 |
52-Week Low | $43.24 | $82.92 |
Typical Hold Time | 93 Days | 50 Days |
Enterprise Value | $111.88B | — |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.45, down 1.21% with bearish technical signals. The company shows strong fundamentals with revenue growth to $32.67B in 2025 and consistent earnings beats. Valuation metrics appear reasonable with P/E of 14.89 and EV/EBITDA of 8.75. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite near-term technical weakness.
GSK presents a mixed outlook with strong profitability and pipeline expansion offset by technical bearishness and HIV patent concerns. The company's 29.73% ROE and recent earnings outperformance support investment appeal, while the bearish moving average signal and competitive pressures warrant caution. Analyst consensus leans hold with 55% neutral rating, suggesting balanced risk-reward for long-term investors.
VYMI trades at $100.53 with a slight 0.3% daily gain, though technical indicators signal bearish momentum with moving averages showing 11 sell signals versus 2 buy signals. The ETF's recent performance includes a 29% one-year return and 14.13% five-year average annual return, with strong institutional interest as firms like Envestnet increased holdings by 22% in Q2 2026. A dividend of $0.82 is scheduled for payment on September 22, 2026.
The outlook for VYMI is mixed; bullish sentiment from Seeking Alpha highlights sector catalysts in financials, energy, and healthcare supporting dividend growth, while technical bearishness and Fed rate hike impacts pose risks. Investors may find value in its 3.61% dividend yield and global diversification, but should monitor financials exposure (43.6% of holdings) amid rising rates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Vanguard International High Dividend Yield ETF
VYMI is an index-based ETF that provides exposure to non-U.S. companies across developed and emerging markets that are characterized by high dividend yields. It tracks the FTSE All-World ex US High Dividend Yield Index, offering a diversified, low-cost way to capture international income while serving as a tactical hedge against U.S. market concentration.
Read more on VYMI →
